THE WOCSI JOURNAL OF MEDICAL SCIENCE

WOUND & OSTOMY CARE SOCIETY OF INDIA

Scope and Challenges of CAR-T Cell Therapy: An Evidence-Based Analysis

Mrs. Parveen[1]

[1]College of Nursing , AIIMS, Rishikesh, Uttarakhand, India

Abstract:

Several local and systemic treatments have been established in the past year, but because the disease situation is heterogeneous, their results have been restricted. Research on therapeutic ways to enhance outcomes is ongoing in oncology. To improve patient outcomes, several immunotherapies and targeted treatments are being explored. A huge percentage of people die from cancer each year. Targeted therapies, like as trastuzumab and imatinib, start becoming available in the first decade of the twenty-first century. These medications locate and eradicate cancer cells by focusing on molecular alterations that are particularly present in cancer cells. Chimeric antigen receptor (CAR)-T therapy is an innovative immunotherapy that has demonstrated a remarkable and long-lasting therapeutic response. Artificial fusion molecules with genetic encoding, known as CARs, could reprogramme peripheral blood polyclonal T-cells to target a specific cell surface target. These uniquely designed compounds enable specifically targeted antibody steered T-cell activation by combining the binding domains from tumor targeting antibodies with T-cell signaling domains.

Keywords : CAR-T Cell Therapy, Oncology, Target Chemotheraphy

Correspondence : Mrs. Parveen Email : dhankaurnani2000@gmail.com

Received: 18/06/2024 Accepted: 24/06/2024 Published: 30/06/2024

Introduction:

Many malignancies are currently treated with dozens of targeted medicines as routine care[1]. Immunotherapy, or treatments that harness and enhance a patient's immune system's ability to combat malignancies, has quickly become the "fifth pillar" of cancer care in the last ten years. Some patients with advanced cancer have proven that immune system-boosting medications can reduce or even completely remove malignancies[1]. In India, in October 2023 the Central Drugs Standard Control agency has approved actaly-cel (actalycabtagene autoleucel for the treatment of leukemia and relapsed or refractory B-cell lymphomas[2]. Though, on June 4, 2021, at the Bone Marrow Transplant unit at ACTREC, Tata Memorial Center in Mumbai, the first trial case for this therapy has already been taken. This was the first case of CAR-T cell therapy (a kind of gene therapy) in India and was the result of collaboration between TMH, the IIT Mumbai team, and cancer care India. The procedure entails several intricate processes, such as taking the patient's T cells out, creating a CAR that targets the cancer, cultivating the CAR T-cells in the laboratory, and then re-infusing them into the patient. This procedure can take two to eight weeks and is quite costly[3]. It is more appealing to proceed with this therapy because of its advantages, which include HLA-independent antigen recognition, activity in both CD4+ and CD8+ T-cells, target antigens

including carbohydrates, proteins, and glycolipids, quick generation of tumor-specific T-cells, low risk of autoimmunity or GVHD, and the fact that it is a living drug that only requires a single infusion[4-5].

CAR T-cells:

Targeting the specific antigen of cancer cells to trigger an immune response against those cells, CAR T-cells are highly skilled at evading the tumor surveillance mechanism, which is characterized by low immunogenicity, antigen modulation, immune suppression by tumor cells T regulatory cells, lymphocytic apoptosis, and defects in the mechanism of MHC-1 production that render cancer cells "invisible" to CD8 cells[4,6]. Cancer cells can be killed by targeting immunity against cancer cells and stimulating the immune system against antigens unique to malignancy. It might involve immune checkpoint blockage and adoptive cell transfer, which can stimulate the immune system non-specifically in CAR-T cell therapy. This marks a turning point in cancer treatment and a move toward customized care. However, it also has a lot of drawbacks in terms of treatment price and clinical efficacy [3], which make for third-world nations with little resources increasingly difficult[1] to go with this treatment. In terms of clinicalefficacy, solid tumors (which account for 70% of pediatric tumors and 90% of adult tumors) and hematological malignancies other **Scopes of CAR-T cell therapyAn effective treatment for B-cell malignancies:** Numerous studies demonstrate how effective this medication is for B-cell malignancies. The most notable of these is the 90% full remission rate in B cell acute lymphoblastic leukemia (B-ALL) treated with anti-CD19 CAR-T cells [7].

Acceptance for CAR-T therapy: Over time, acceptability of CAR-T therapy has improved. This specialized therapy is now more widely accepted. In certain regions, it is clearly established as a drug of last resort, or a second line of treatment. This treatment may be taken into consideration in the early stages of treatment for some medical disorders, such as high-risk lymphoma. Patients will benefit from a

than B cells are not well treated by this therapy. Apart from developed countries, this region of the world struggles with money, sophisticated technology, a skilled labor force to create and implement these treatments, and a dearth clear, appropriate regulations. In terms of clinical efficacy, solid tumors (which account for 70% of pediatric tumors and 90% of adult tumors) and hematological malignancies other than B cells are not well treated by this therapy. Apart from these countries, this region of the world struggles with money, sophisticated technology, a skilled labor force to create and implement these treatments, and a dearth of clear, appropriate regulations. Clinical drawbacks of CAR-T cell treatment include, but are not limited to, the following: limited tumor penetration, and antigen escape, severe toxicities that could be fatal, and host and tumor microenvironment[6]. Cytokine-Release Syndrome (CRS), neurological toxicity, B-cell aphasia, tumor lysis syndrome, and allergy are the most frequent side effects of CAR-T cell therapy[5-6]. A breakthrough in the treatment of cancer, CAR-T cell therapy is still in its infancy. While this has partially redirected the researchers' focus to tailored therapy, it has also raised several extremely challenging and perplexing problems. This article will give a thorough summary of the status of CAR-T-cell therapies, outlining their application, current difficulties, and anticipated advancements in the future.

CAR rather than receiving further rounds of conventional chemotherapy in this way[8].

CAR-T cell therapy beyond cancer treatment: outside the realm of cancer care although there are currently few CAR-T-cell treatments in the market, chimeric antigen receptor (CAR)-T-cell therapies have shown impressive success in the treatment of hematologic malignancies. Moreover, CAR-T cells have demonstrated encouraging potential for broadening their therapeutic uses to a variety of conditions, such as solid tumors, autoimmune (antisynthetase syndrome, systemic lupus erythematosus, and liver fibrosis), fibrotic diseases (HIV, Hep B & C, and Human Cytomegalovirus), and infectious diseases[5].

Challenges with CAR-T cell therapy : CAR-T cell therapy is considered a breakthrough in the cancer treatment, but there are lots of challenges which are considered as major hurdles to adopt it as a promising alternative to conventional therapy and some of these are as following:

Antigen escape: A single antigen expressed by cancer cells is the target of CAR-T cells, yet these cells typically exhibit partial or complete loss of target antigen expression. The only cells that can attack cancer cells are CAR-t cells when enough antigens are present [9].

Severe adverse events: Although the treatment has demonstrated encouraging outcomes in the treatment of hematological malignancies, its potentially fatal side effects, including cytokine-release syndrome (CRS) and immunological effector cell-associated neurotoxicity syndrome (ICANS), are a cause for concern[9-10]. Anaphylaxis, tumor lysis syndrome, and B-cell aphasia are among the other most often reported adverse effects.

Target antigen heterogeneity: Antigen heterogeneity, or the variation in antigen expression on the cells within a particular tumor, is a key drawback of CAR-T cell treatment for solid tumors. The degree to which these processes take place will probably be important in determining the antigen expression thresholds that will be utilized to identify people who qualify [11]. Unfortunately, it is unclear how much of a tumor must express the target antigen for treatment to be effective.

High cost of manufacturing autologous CAR-T cells: These cells are extremely expensive to produce, and the cost increases significantly in cases of severe CRS (cytokine-release syndrome). Furthermore, the production turnaround time for autologous CAR T cells ranges from 21 to 35 days[10]. Patients may need bridging therapy during this waiting period, and in certain situations, they pass away from quickly progressing illnesses without reaping the benefits of CAR-T cell therapy. It is likely that T cells from ill donors become exhausted and become less active than T cells from donors who are in good health[10].

Ineffectiveness against solid tumors: Solid tumors account for around 30% of cancers in children and 90% of malignancies in adults. Although this treatment has led to previously unheard-of outcomes for hematological malignancies, the results are much less striking when it comes to solid tumors. Studies have indicated that immunosuppressive tumor microenvironment (TME) and lack of tumor-exclusive target are the causes of the same[1,9-10,12].

Safety switch and controllable CAR: Patient safety is of utmost importance as gene and cell therapies progress. One of the potential risks is therapy-induced tumorigenesis, whereby the insertion of therapeutic genes may cause insertional mutagenesis or activate oncogenes that regulate tumor growth. Furthermore, because it is a living drug, the body may retain it for an extended period. Since some healthy cells normally express the target antigens of CAR-T cells, the long-term survival of these cells may endanger public health by specifically targeting healthy cells[10]. The addition of a safety switch and regulated CAR can lessen these kinds of detrimental consequences, but this is a challenging task.

Future prospectives : Much effort is being put into improving this therapy's feasibility, effectiveness, and cost-effectiveness. The following are some of the breakthroughs, theoretical underpinnings, and outcomes of clinical trials:

Cost-effectiveness: Researchers are working on off-the-shelf (allogenic) CAR T-cell treatment, which will speed up the manufacturing process and reduce the cost and increase the accessibility of this therapy[11]. There is potential for in vivo methods such implantable scaffolds (m-RNA based technology) to increase the accessibility and lower the cost of CAR T-cell therapy[1,3].

Shortened manufacturing time: Research is ongoing, and even a pre-clinical study has demonstrated that T-cells isolated from peripheral blood can be used to generate functional CAR-T cells in less than 24 hours without the need for T cell activation[3].

Improved efficacy and spectrum of treatment: Many novel strategies, such as combining CAR T-cell therapy with mRNA vaccines and oncolytic viruses, "armored" CARS (which can navigate challenging microenvironments by secreting specific cytokines and other molecules), and reconditioning the tumor microenvironment, are being investigated to increase the effectiveness of CAR T-cell therapy in solid tumors[3,10]. CAR-T therapy can be utilized in combination with immunological checkpoint inhibitors, chemotherapy, radiation, and oncolytic viruses for safety and efficacy as indicated[5].

Preventing severe adverse events: According to certain research findings, treating cancer patients with CAR T-cell treatment when their tumor burden is minimal and metastases are early can minimize serious side effects[10]. In addition, a safety switch or adjustable CAR can fulfill this function by rapidly exhausting or shutting off in the event of a potentially fatal toxicity. CAR T cells can be eliminated once the cancer has been cured to prevent long-term negative effects from the destruction of healthy tissues that express targets.

Enhance specificity of CAR-T cell therapy: Engineering T cells to produce dual CARs, which detect two or more different antigens present on the same cancer cell, is one method to improve the specificity of CAR T cell treatment. This strategy can minimize damage to healthy cells that express CAR-T antigens while specifically targeting and eliminating only cancer cells that exhibit both antigens[9]. Anticancer efficacy can be established in solid tumors with controllable toxicity, even if the target is expressed in certain normal tissues. The fact that high antigen density is necessary for CAR T cells to achieve complete effector function. Trials are underway to determine whether administering numerous doses of CAR-T cells improves the response to cancer and lessens symptoms associated with cancer[1].

The next generation of CAR-T cells: In order to get around the drawbacks of the CAR-T cell therapies that are already in the market, like high toxicity and poor efficacy, researchers have created a number of next-generation CAR-T designs. [13-14].

More than just CAR-T cells/Future perspective: The surprising success of CAR-T cell therapy has motivated researchers to investigate the possibility of therapeutically manipulating natural killer (NK) cells, macrophages, and neutrophils, among other immune cells[15]. Additionally, research is being conducted on additional immune. cells, such as tumor-infiltrating lymphocytes (TILs), which use immune cells that have infiltrated the surrounding tissue of the tumor. Unlike CARs, which use segments of synthetic antibodies that can only target particular antigens on the surface of cells, specially engineered T-cells (TCRs) use naturally occurring receptors that can also recognize antigens inside tumor cells[1].

Conclusion:

A new era in medicine has begun with the use of chimeric antigen receptor T-cells (CAR-T cells) for treatment. It is perhaps the largest invention of this era. Through the modification of the patient's immune system to identify and then combat cancer cells, CAR-T cell therapy is transforming the way tumors are treated. A step toward customized treatments is CAR-T cell therapy. When no further treatment is required, its success rate for a long-lasting remission range from 30% to 40%. These cells usually take 30 to 90 minutes to infuse. Clinical trials with CAR-T cells have demonstrated remarkable remission rates of up to 93% in cases of severe blood cancer, specifically B-cell carcinomas. Patients undergoing CAR-T cell therapy remain in the hospital for a minimum of seven days following their treatment. Although CAR T-cell therapy lacks efficacy in solid tumors and is complicated and expensive to manufacture, it may offer some patients a long-term remission from blood malignancies. The success of CAR T cell therapy in the future will depend on ongoing research into solid tumor formation, off-the-shelf CAR T cell therapy, safety, cost, and non-cancer disorders. The development of CAR T cell treatment emphasizes the value of ongoing funding for innovation and scientific research. Future advancements in the treatment of cancer

and other illnesses are expected given the broad.However, recent advancements in the field provide patients optimism for increased accessibility and effectiveness in treating a wider range of cancer types as well as other illnesses.

References:

[1] CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI [Internet]. 2013 [cited 2024 May 30]. Available from: https://www.cancer.gov/about-cancer/treatment/research/car-t-cells

[2] www.aabb.org [Internet]. [cited 2024 Jun 9]. India Celebrates First Homegrown CAR T-Cell Therapy. Available from: https://www.aabb.org/news-resources/news/article/2024/04/10/india-celebrates-first-homegrown-car-t-cell-therapy

[3] clients_merit. A Rundown of New Developments in CAR T-cell Therapy [Internet]. MERIT CRO. 2022 [cited 2024 May 31]. Available from: https://meritcro.com/a-rundown-of-new-developments-in-car-t-cell-therapy/

[4] SlideShare [Internet]. 2018 [cited 2024 May 30]. CAR- T Cell. Available from: https://www.slideshare.net/slideshow/car-t-cell-90814883/90814883

[5] Wang JY, Wang L. CAR-T cell therapy: Where are we now, and where are we heading? Blood Sci. 2023 Nov 2;5(4):237–48.

[6] Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021 Apr 6;11(4):1–11.

[7] Wang Z, Wu Z, Liu Y, Han W. New development in CAR-T cell therapy. J Hematol OncolJ Hematol Oncol. 2017 Feb 21;10(1):53.

[8] Glasgow G. The Latest News About CAR T-Cell Therapy [Internet]. [cited 2024 May 30]. Available from: https://news.cuanschutz.edu/cancer-center/car-t-cell-therapy-update

[9] Mehrabadi AZ, Ranjbar R, Farzanehpour M, Shahriary A, Dorostkar R, Hamidinejad MA, et al. Therapeutic potential of CAR T cell in malignancies: A scoping review. Biomed Pharmacother. 2022 Feb 1;146:112512.

[10] Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol [Internet]. 2023 May 15 [cited 2024 May 31];14. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1188049/full.

[11] Newick K, O'Brien S, Moon E, Albelda SM. CAR T Cell Therapy for Solid Tumors. Annu Rev Med. 2017 Jan 14;68(Volume 68, 2017):139–52.

[12] De Marco RC, Monzo HJ, Ojala PM. CAR T Cell Therapy: A Versatile Living Drug. Int J Mol Sci. 2023 Mar 27;24(7):6300.

[13] Tomasik J, Jasiński M, Basak GW. Next generations of CAR-T cells - new therapeutic opportunities in hematology? Front Immunol [Internet]. 2022 Oct 28 [cited 2024 May 30];13. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1034707/full

[14] Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Hashem S, et al. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J Transl Med. 2023 Jul 7;21(1):449.

[15] Sun D, Shi X, Li S, Wang X, Yang X, Wan M. CAR- T cell therapy: A breakthrough in traditional cancer treatment strategies (Review). Mol Med Rep. 2024 Mar 1;29(3):